অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

chiesi australia pty ltd - mesalazine, quantity: 1.6 g - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; sodium starch glycollate type a; hypromellose; colloidal anhydrous silica; magnesium stearate; macrogol 6000; methacrylic acid copolymer; triethyl citrate; glyceryl monostearate; polysorbate 80; sodium hydroxide; maize starch; iron oxide red; iron oxide yellow; monobasic potassium phosphate - asacol is indicated for the treatment of mild to moderate ulcerative colitis and maintenance of remission in adults.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - mesalazine, quantity: 1200 mg - tablet, modified release - excipient ingredients: methacrylic acid copolymer; purified talc; silicon dioxide; sodium starch glycollate; stearic acid; iron oxide red; carmellose sodium; carnauba wax; magnesium stearate; titanium dioxide; macrogol 6000; triethyl citrate - for the induction and maintenance of remission in patients with mild to moderate, active ulcerative colitis.

ইস্রায়েল - ইংরেজি - Ministry of Health

padagis israel agencies ltd, israel - azathioprine - film coated tablets - azathioprine 25 mg - azathioprine - azathioprine - immunosuppressive agent used in transplantation surgery for suppression of graft rejection. for special cases of rheumatoid arthritis- not responsive to other agents- and only by rheumatology experts in hospitals or rheumatic clinics.

ইস্রায়েল - ইংরেজি - Ministry of Health

padagis israel agencies ltd, israel - azathioprine - film coated tablets - azathioprine 50 mg - azathioprine - azathioprine - immunosupressive agent used in transplantation surgery for suppression of graft rejection. for special cases of rheumatoid artritis, not responsive to other agents, and only by rheumatology experts in hospitals or rheumatic clinics.

কানাডা - ইংরেজি - Health Canada

sanis health inc - azathioprine - tablet - 50mg - azathioprine 50mg - immunosuppressive agents

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - methotrexate, quantity: 10 mg - tablet - excipient ingredients: calcium hydrogen phosphate; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; purified talc; magnesium stearate - antineoplastic chemotherapy,treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methotrexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides.,psoriasis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),because of the high risk attending to its use, methotrexate is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations.,rheumatoid arthritis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see sections 4.4 special warnings and precautions for use and 4.5 interactions with other medicines and other forms of interactions).,steroids may be reduced gradually in patients who respond to methotrexate.,combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - methotrexate, quantity: 2.5 mg - tablet - excipient ingredients: calcium hydrogen phosphate; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; purified talc; magnesium stearate - antineoplastic chemotherapy,treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. methotrexate is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides.,psoriasis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),because of the high risk attending to its use, methotrexate is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations.,rheumatoid arthritis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see sections 4.4 special warnings and precautions for use and 4.5 interactions with other medicines and other forms of interactions).,steroids may be reduced gradually in patients who respond to methotrexate.,combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - methotrexate, quantity: 10 mg - tablet - excipient ingredients: calcium hydrogen phosphate; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; purified talc; magnesium stearate - antineoplastic chemotherapy,treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. imutrex is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides.,psoriasis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),because of the high risk attending to its use, imutrex is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations.,rheumatoid arthritis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see sections 4.4 special warnings and precautions for use and 4.5 interactions with other medicines and other forms of interactions).,steroids may be reduced gradually in patients who respond to methotrexate.,combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - methotrexate, quantity: 2.5 mg - tablet - excipient ingredients: calcium hydrogen phosphate; lactose monohydrate; sodium starch glycollate type a; microcrystalline cellulose; purified talc; magnesium stearate - antineoplastic chemotherapy,treatment of breast cancer, gestational choriocarcinoma and in patients with chorioadenoma destruens and hydatidiform mole. palliation of acute and subacute lymphocytic leukaemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias. in combination with corticosteroids, methotrexate may be used for induction of remission. the drug is now most commonly used for the maintenance of induced remissions. imutrex is also effective in the treatment of the advanced stages (iii and iv, peters staging system) of lymphosarcoma, particularly in children and in advanced cases of mycosis fungoides.,psoriasis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),because of the high risk attending to its use, imutrex is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and / or after dermatologic consultations.,rheumatoid arthritis chemotherapy,(see warnings box and section 4.4 special warnings and precautions for use),management of severe, recalcitrant, active rheumatoid arthritis in adults not responding to or intolerant of an adequate trial of nsaids and one or more disease modifying drugs. aspirin, nsaids and/or low dose steroids may be continued, although the possibility of increased toxicity with concomitant use of nsaids including salicylate has not been fully explored (see sections 4.4 special warnings and precautions for use and 4.5 interactions with other medicines and other forms of interactions).,steroids may be reduced gradually in patients who respond to methotrexate.,combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine or cytotoxic agents has not been studied and may increase the incidence of adverse effects. rest and physiotherapy as indicated should be continued.